BRUSSELS, Nov 2 (Reuters) - Belgian cancer diagnosis and therapy company Ion Beam Applications (IBAB.BR) said on Tuesday it had signed a deal worth $70-80 million over ten years to construct a new therapy centre in Knoxville, Tennessee.
In a statement IBA, which sells cancer-fighting machines and radioactive products used in molecular imaging, said it had been selected by the ProVision Trust to supply and install the new proton therapy facility, and provide operation and maintenance services for a period of ten years.
IBA said the deal, which is still subject to financing, would reinforce its leadership in particle therapy treatment, with its facilities currently accounting for more than half of all proton therapy centres worldwide. “We are proud to collaborate with ProVision in making proton therapy accessible to more cancer patients in the USA,” IBA Chief Executive Officer Pierre Mottet said of the planned facility, which is due to be operational by 2013.
The company said in August that first-half sales were barely changed at 181.3 million euros ($252.8 million) and its recurring operating profit flat at 8.6 million. [ID:nLDE67T1PO] ($1=.7172 Euro) (Reporting by Charlie Dunmore; Editing by Jon Loades-Carter)